Back to Search
Start Over
A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes.
- Source :
-
Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2023 Jun 08; Vol. 36, pp. 11367. Date of Electronic Publication: 2023 Jun 08 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Long-term success in beta-cell replacement remains limited by the toxic effects of calcineurin inhibitors (CNI) on beta-cells and renal function. We report a multi-modal approach including islet and pancreas-after-islet (PAI) transplant utilizing calcineurin-sparing immunosuppression. Ten consecutive non-uremic patients with Type 1 diabetes underwent islet transplant with immunosuppression based on belatacept (BELA; n = 5) or efalizumab (EFA; n = 5). Following islet failure, patients were considered for repeat islet infusion and/or PAI transplant. 70% of patients (four EFA, three BELA) maintained insulin independence at 10 years post-islet transplant, including four patients receiving a single islet infusion and three patients undergoing PAI transplant. 60% remain insulin independent at mean follow-up of 13.3 ± 1.1 years, including one patient 9 years after discontinuing all immunosuppression for adverse events, suggesting operational tolerance. All patients who underwent repeat islet transplant experienced graft failure. Overall, patients demonstrated preserved renal function, with a mild decrease in GFR from 76.5 ± 23.1 mL/min to 50.2 ± 27.1 mL/min ( p = 0.192). Patients undergoing PAI showed the greatest degree of renal impairment following initiation of CNI (56% ± 18.7% decrease in GFR). In our series, repeat islet transplant is ineffective at maintaining long-term insulin independence. PAI results in durable insulin independence but is associated with impaired renal function secondary to CNI dependence.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Wisel, Posselt, Szot, Nunez, Santos-Parker, Gardner, Worner, Roll, Syed, Kelly, Ward, Tavakol, Johnson, Masharani and Stock.)
- Subjects :
- Humans
Insulin therapeutic use
Calcineurin
Immunosuppression Therapy methods
Calcineurin Inhibitors therapeutic use
Immunosuppressive Agents therapeutic use
Pancreas Transplantation
Diabetes Mellitus, Type 1 drug therapy
Diabetes Mellitus, Type 1 surgery
Islets of Langerhans Transplantation methods
Subjects
Details
- Language :
- English
- ISSN :
- 1432-2277
- Volume :
- 36
- Database :
- MEDLINE
- Journal :
- Transplant international : official journal of the European Society for Organ Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 37359825
- Full Text :
- https://doi.org/10.3389/ti.2023.11367